Renaissance Technologies
VRCA icon

Renaissance Technologies’s Verrica Pharmaceuticals VRCA Stock Holding History

Renaissance Technologies’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$133K Sell
21,769
-10,591
-33% -$66K ﹤0.01% 2946
2026
Q1 		$171K Buy
32,360
+5,960
+23% +$38.2K ﹤0.01% 2941
2025
Q4 		$219K Sell
26,400
-2,791
-10% -$15.5K ﹤0.01% 2863
2025
Q3 		$126K Buy
29,191
+20,471
+235% +$123K ﹤0.01% 3226
2025
Q2 		$46.2K Buy
+8,720
New +$46.9K ﹤0.01% 3405
2025
Q1 		– Sell
-23,330
Closed -$163K – 3874
2024
Q4 		$163K Buy
23,330
+8,534
+58% +$93.8K ﹤0.01% 3215
2024
Q3 		$215K Buy
14,796
+10,243
+225% +$461K ﹤0.01% 3105
2024
Q2 		$332K Buy
+4,553
New +$350K ﹤0.01% 2869
2023
Q4 		– Sell
-6,810
Closed -$265K – 4174
2023
Q3 		$265K Sell
6,810
-9,120
-57% -$463K ﹤0.01% 2990
2023
Q2 		$919K Buy
15,930
+10,280
+182% +$624K ﹤0.01% 2517
2023
Q1 		$367K Sell
5,650
-9,987
-64% -$604K ﹤0.01% 3027
2022
Q4 		$430K Sell
15,637
-7,393
-32% -$197K ﹤0.01% 3034
2022
Q3 		$672K Buy
23,030
+18,240
+381% +$625K ﹤0.01% 2734
2022
Q2 		$92K Buy
+4,790
New +$241K ﹤0.01% 3873
2020
Q1 		– Sell
-1,390
Closed -$221K – 3838
2019
Q4 		$221K Buy
+1,390
New +$205K ﹤0.01% 3168

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies's VRCA Position: Q2 2026 in Review

Renaissance Technologies reduced its Verrica Pharmaceuticals (VRCA) stake by 33% in Q2 2026, selling an estimated $66K and leaving 21,769 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #2946.

Renaissance Technologies first reported a position in VRCA in Q4 2019 and has held it in 15 quarters since. The position peaked at $919K in Q2 2023. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.

  • Renaissance Technologies held 21,769 shares of Verrica Pharmaceuticals worth $133K as of Q2 2026.
  • Renaissance Technologies sold 10,591 Verrica Pharmaceuticals shares in Q2 2026, an estimated $66K.
  • Verrica Pharmaceuticals made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2946 holding.
  • Renaissance Technologies first reported a position in Verrica Pharmaceuticals in Q4 2019 and has held it in 15 quarters since.
  • Renaissance Technologies's Verrica Pharmaceuticals position peaked at $919K in Q2 2023.
  • 43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.